New drug shows promise for treating chronic neuropathic pain

A non-opioid designer molecule for treating chronic neuropathic pain by calming hyperactive pain-sensing neurons in the peripheral nervous system has had promising results in a preclinical study conducted by researchers at Weill Cornell Medicine and the Burke Neurological Institute.

Related Keywords

United Kingdom ,British ,Gareth Tibbs ,Steven Fox ,Megan Craig ,Peter Goldstein ,Larry Schlossman ,Dianna Willis ,Burke Neurological Institute ,Technology Licensing ,Daedalus Fund For Innovation ,Research Collaborations ,Cornell Center ,Akelos Inc ,Office Of Biopharma Alliances ,Weill Cornell Medicine Department Of Anesthesiology ,Research Institute At Weill Cornell Medicine ,Presbyterian Weill Cornell Medical Center ,National Institutes Of Health ,Weill Cornell Medicine ,Burke Neurological ,British Journal ,Feil Family Brain ,Mind Research Institute ,Weill Cornell ,Weill Cornell Medical ,Daedalus Fund ,Weill Cornell Medicine Enterprise Innovation ,Biopharma Alliances ,National Institutes ,Neuropathic Pain ,Rain ,Reclinical ,Anesthesiology ,Fell ,Hronic ,Clinical Trial ,Son ,Medicine ,Embrane ,Olecule ,Nervous System ,Eurons ,Neuroscience ,Research ,Technology ,Herapeutics ,